Referenser

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. d., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P. B., Schraub, S., Sneeuw, K., Sullivan, M., & Takeda, F. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. JNCI Journal of the National Cancer Institute, 85(5), 365–376.

Bruhn, H. (2025). PROGNOSTIC FACTORS FOR GLIOBLASTOMA SURVIVAL IN A CLINICAL CONTEXT : The role of presenting symptoms and treatments. Linköping University Electronic Press.

Fekete, B., Werlenius, K., Tisell, M., Pivodic, A., Smits, A., Jakola, A. S., & Rydenhag, B. (2023). What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome. Frontiers in Surgery, 10.

Johansson, B., Starmark, A., Berglund, P., Rödholm, M., & Rönnbäck, L. (2009). A self-assessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries. Brain Injury, 24(1), 2–12.

Kinhult, S., Tavelin, B., Löfgren, D., Rosenlund, L., Sandström, M., Strandeus, M., & Henriksson, R. (2023). Regional variation i användningen av TTF vid glioblastombehandling. Läkartidningen, 2003;120:22158.

Löfgren, D., Valachis, A., & Olivecrona, M. (2022). Older meningioma patients: A retrospective population-based study of risk factors for morbidity and mortality after neurosurgery. Acta Neurochirurgica, 164(11), 2987–2997.

Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., Deimling, A. von, & Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncology, 23(8), 1231–1251.

Osoba, D., Aaronson, N. K., Muller, M., Sneeuw, K., Hsu, M.-A., Yung, W. K. A., Brada, M., & Newlands, E. (1996). The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Quality of Life Research, 5(1), 139–150.

Rosenlund, L., Henriksson, R., Asklund, T., & Petersson, L. (2014). P15.14 * DEVELOPING PATIENT REPORTED OUTCOME MEASURES (PRO) FOR IMPLEMENTATION IN THE SWEDISH NATIONAL QUALITY REGISTER FOR PRIMARY BRAIN TUMORS. Neuro-Oncology, 16(suppl 2), ii76–ii77.

Taphoorn, M. J. B., Claassens, L., Aaronson, N. K., Coens, C., Mauer, M., Osoba, D., Stupp, R., Mirimanoff, R. O., Bent, M. J. van den, & Bottomley, A. (2010). An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. European Journal of Cancer, 46(6), 1033–1040.

Thurin, E., Corell, A., Gulati, S., Smits, A., Henriksson, R., Bartek, J., Jr, Salvesen, Ø., & Jakola, A. S. (2019). Return to work following meningioma surgery: A Swedish nationwide registry-based matched cohort study. Neuro-Oncology Practice, 7(3), 320–328.

Yarabarla, V., Mylarapu, A., Han, T. J., McGovern, S. L., Raza, S. M., & Beckham, T. H. (2023). Intracranial meningiomas: An update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy. Frontiers in Oncology, 13.